Evaluation of the Venous Excess Ultrasound Score (VExUS) After Circulating Volume Modification in Children.

NCT ID: NCT06695546

Last Updated: 2026-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

67 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-10

Study Completion Date

2025-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Venous overload has an impact on peripheral organ perfusion and on the short- and long-term prognosis of intensive care patients. The VExUS ultrasound score is a new tool whose parameters can be used to estimate this impact. This score was initially evaluated and validated on an adult population. ) In children, there is only one study looking at the use and applicability of this VExUS score, highlighting its feasibility in a paediatric population, as well as a possible correlation between elevated central venous pressure and altered renal Doppler (one of the score's components).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Volume Expansion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Patients over one year of age treated at Toulouse University Hospital and receiving extrarenal purification, bloodletting or vascular filling \> 10 ml/kg.

VExUS evaluation ultrasound

Intervention Type OTHER

VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:

* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.
* Hepatic venous Doppler measurement in pulsed Doppler mode.
* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VExUS evaluation ultrasound

VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:

* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.
* Hepatic venous Doppler measurement in pulsed Doppler mode.
* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Children aged between 1 and 18 years, receiving extrarenal purification with UF \> 10 ml/kg, bleeding \> 10 ml/kg or vascular filling \> 10 ml/kg

Exclusion Criteria

* Refusal of the patient or opposition of one or both holders of parental authority.
* Minors with parental authority.
* Ultrafiltration time \> 6h.
* Curarized patient, known abnormality of the hepatorenal venous network.
* Patient agitated or poor tolerance of the examination.
* Parents under court protection, guardianship or curatorship.
Minimum Eligible Age

1 Year

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Toulouse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Montserrat SIERRA COLOMINA, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Toulouse

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC31/24/0457

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Contrast Enhanced Ultrasound in COVID-19
NCT04640038 COMPLETED PHASE3
Effectiveness of Contrast-Enhanced Ultrasound
NCT03473249 ACTIVE_NOT_RECRUITING PHASE4